(Photo Courtesy: www.traceepersiko.com)
New data regarding Ganymed Pharmaceuticals' drug IMAB362, presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, provides hope for a subset of gastric and gastroesophageal junction adenocarcinoma (gastric cancer) patients with an advanced form of the disease, according to an analyst with research and consulting firm GlobalData.
As explored in GlobalData's gastric cancer report, incidences of the disease are set to increase to over 410,000 by 2024 across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and China, which is indicative of the growing need for effective gastric cancer drugs, and the potential market open to IMAB362.
A randomized, open-label Phase II trial named FAST (NCT01630083) demonstrated that IMAB362, in combination with EOX (epirubicin, oxaliplatin, and capecitabine) chemotherapy, significantly improved patients' progression-free survival and overall survival of previously untreated, claudin18.2-positive advanced gastric cancer patients compared with EOX alone.
Progression free survival was 7.9 months with IMAB362, versus 4.8 months with EOX alone, while overall survival was 13.2 months versus 8.4 months.
Indeed, IMAB362 is the first drug to have shown a survival benefit for gastric cancer patients in the first-line setting since the approval of Roche's Herceptin (trastuzumab) in 2010.